Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | MC5R | P33032 | 4/20 | 0.56 |
| ▸ | MC4R | P32245 | 3/20 | 0.56 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.55 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | MC3R | P41968 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.50 |
| ▸ | MC1R | Q01726 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13021557 | 0.85 | MC5R (0.54) | FFAR1CYP1A2MC5RMC4RHDAC3 | |
| SCHEMBL13783950 | 0.84 | HDAC3 (0.67) | FFAR1CYP1A2MC5RMC4RS1PR4 | |
| SCHEMBL4923929 | 0.83 | HDAC8 (0.66) | FFAR1MC5RMC4RHDAC3HDAC1 | |
| SCHEMBL25044160 | 0.83 | CYP1A2 (0.64) | FFAR1CYP1A2S1PR4S1PR5HDAC1 | |
| SCHEMBL7446128 | 0.82 | MEN1 (0.54) | FFAR1MC5RMC4RHDAC3HDAC1 | |
| SCHEMBL19851537 | 0.82 | HDAC8 (0.53) | FFAR1CYP1A2MC5RMC4RHDAC3 | |
| SCHEMBL6008141 | 0.81 | MC5R (0.71) | CYP1A2MC5RMC4RHDAC3HDAC1 | |
| SCHEMBL4017226 | 0.80 | MC5R (0.65) | CYP1A2MC5RMC4RMC3RMAPK1 | |
| SCHEMBL947200 | 0.79 | FFAR1 (0.59) | FFAR1CYP1A2S1PR5 | |
| SCHEMBL156664 | 0.79 | MEN1 (0.56) | FFAR1HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203096-A1 | EPHA4 TARGETING COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-29 | — | — | US | disclosed |
| EP-4139326-A1 | EPHA4 TARGETING COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-01 | — | — | EP | disclosed |
| WO-2021217047-A1 | EPHA4 TARGETING COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-10-28 | — | — | WO | disclosed |
| US-20040044210-A1 | Miniaturization; network of hydrogen bonding | PURDUE RESEARCH FOUNDATION | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203096-A1 | EPHA4 TARGETING COMPOUNDS AND METHODS OF USE THEREOF | EPHA4, EPHA1, EPHA5 | FFAR1 2748/4885CYP1A2 3007/4885MC5R 3248/4885 |
| US-20040044210-A1 | Miniaturization; network of hydrogen bonding | CTCF, MYCBP, APLNR | FFAR1 3088/4885CYP1A2 3921/4885MC5R 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.